肿瘤生物製药市场机会、成长驱动因素、产业趋势分析及预测（2025-2034年）

2024 年全球肿瘤生物製药市场价值为 1,306 亿美元，预计到 2034 年将以 7.5% 的复合年增长率成长至 2,683 亿美元。

受全球癌症发病率不断攀升以及对个人化和标靶治疗方案日益增长的需求驱动，市场正经历变革性阶段。新一代定序、免疫疗法和人工智慧驱动的药物研发领域的持续突破正在重塑癌症的治疗和检测方式。过去一年，新的治疗创新和先进生物製剂的可及性提升，重新定义了血液肿瘤和实体肿瘤的治疗标准。精准肿瘤学技术正在加强早期诊断，并实现个人化治疗，从而提高患者的存活率。有利的政府政策、不断增加的医疗保健投资以及不断完善的监管路径，都为市场扩张提供了支持。肿瘤生物製药产业透过根据每位患者的分子特征客製化治疗方案，持续引领精准医疗的转型。生物製剂、免疫疗法的进步以及精准医疗实践的日益普及，进一步推动了该行业的成长，以满足全球对更有效癌症管理的迫切需求。

2024年，单株抗体市场占37.6%的市场份额，预计到2034年将达到960亿美元，年复合成长率达7%。单株抗体是现代肿瘤治疗的基石，因为它们是高度特异性的生物製剂，能够与癌细胞表面表达的独特抗原结合。这些标靶疗法透过直接攻击肿瘤细胞、阻断肿瘤生长讯号传导以及刺激免疫活性来清除癌组织。与传统化疗相比，单株抗体具有更佳的安全性，能够最大限度地减少脱靶效应并提高治疗的精准性。

2024年，肺癌应用领域市场规模预计将达375亿美元。肺癌仍然是全球最致命的癌症类型，其中非小细胞肺癌（NSCLC）约占所有病例的85%。精准治疗和免疫肿瘤疗法的日益普及，推动了市场格局的重大变革。针对特定基因和分子标靶的现代治疗进展，显着改善了患者的治疗效果和成功率。

预计到2024年，美国肿瘤生物製药市场规模将达到519亿美元。人工智慧技术的进步正在革新癌症诊断，并加速下一代肿瘤药物的研发。然而，获得这些先进疗法的机会不均等仍然是一个持续存在的挑战，尤其是在弱势群体中。美国在推动生物相似药和个人化疗法方面持续取得进展，并大力投资以提高药物可及性，增强患者获得细胞疗法和免疫疗法的机会。

肿瘤生物製药市场的主要参与者包括艾伯维（AbbVie）、安进（Amgen）、阿斯特捷利康（AstraZeneca）、拜耳（Bayer）、百健（Biogen）、百时美施贵宝（Bristol-Myers Squibb）、礼来（Eli Lilly）、罗氏（F.Hoffbb-La RocheK、Koffline） Johnson）、默克（Merck）、诺华（Novartis）、辉瑞（Pfizer）、赛诺菲（Sanofi）、武田製药（Takeda Pharmaceutical）、山德士（Sandoz）、百康（Biocon）、赛尔特隆（Celltrion）、Adaptimmune、传奇生物（Legend Biotech）和安赛乐乐（Arx）。为了巩固其在全球肿瘤生物製药市场的地位，各大公司正致力于策略合作、併购，以拓展其肿瘤产品线并加速药物研发。各公司正在扩大与生物技术创新者的研究合作，共同开发标靶生物製剂和免疫疗法。对人工智慧、基因组学和分子谱分析等先进技术的投资正被优先考虑，以增强精准医疗能力。各公司也在努力与监管机构达成一致，以加快产品审批速度并扩大地域覆盖范围。

目录

第一章：方法论与范围

第二章：执行概要

第三章：行业洞察

• 产业生态系分析
  • 供应商格局
  • 每个阶段的价值增加
  • 影响价值链的因素
• 产业影响因素
  • 成长驱动因素
    • 全球癌症发生率上升和人口老化
    • 免疫疗法和标靶生物製剂的进展
    • 生物标记驱动和精准肿瘤学的扩展
    • 加大监管力度，加速审核速度
  • 产业陷阱与挑战
    • 生物製剂价格高昂，低收入地区难以负担
    • 复杂的製造和供应链物流
  • 市场机会
    • 肿瘤非特异性和泛癌疗法的扩展
    • 数位健康和​​远端监测工具的普及应用日益广泛
• 成长潜力分析
• 监管环境
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲
• 技术格局
  • 当前技术趋势
  • 新兴技术
• 未来市场趋势
• 管道分析
• 波特的分析
• PESTEL 分析

第四章：竞争格局

• 介绍
• 公司市占率分析
  • 全球的
  • 北美洲
  • 欧洲
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 关键进展
  • 併购
  • 伙伴关係与合作
  • 新产品发布
  • 扩张计划

第五章：市场估算与预测：依产品类型划分，2021-2034年

• 主要趋势
• 单株抗体
• 免疫检查点抑制剂
• 细胞和基因疗法
• 抗体药物偶联物（ADC）
• 癌症疫苗
• 其他产品类型

第六章：市场估计与预测：依癌症类型划分，2021-2034年

• 主要趋势
• 肺癌
• 乳癌
• 大肠直肠癌
• 摄护腺癌
• 白血病和淋巴瘤
• 黑色素瘤
• 卵巢癌和子宫颈癌
• 其他癌症类型

第七章：市场估计与预测：依给药途径划分，2021-2034年

• 主要趋势
• 口服
• 肠外
• 其他给药途径

第八章：市场估算与预测：依药物类型划分，2021-2034年

• 主要趋势
• 专有（品牌）
• 生物相似药

第九章：市场估算与预测：依配销通路划分，2021-2034年

• 主要趋势
• 医院药房
• 药局和零售药房
• 网路药局

第十章：市场估计与预测：依地区划分，2021-2034年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十一章：公司简介

• AbbVie
• Amgen
• AstraZeneca
• Bayer
• Biogen
• Bristol-Myers Squibb
• Eli Lilly
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Johnson & Johnson
• Merck
• Novartis
• Pfizer
• Sanofi
• Takeda Pharmaceutical
• Sandoz
• Biocon
• Celltrion
• Adaptimmune
• Legend Biotech
• Arcellx

The Global Oncology Biopharmaceuticals Market was valued at USD 130.6 Billion in 2024 and is estimated to grow at a CAGR of 7.5% to reach USD 268.3 Billion by 2034.

The market is witnessing a transformative phase driven by the growing worldwide incidence of cancer and the rising need for personalized and targeted treatment solutions. Continuous breakthroughs in next-generation sequencing, immunotherapy, and AI-powered drug development are reshaping how cancer is treated and detected. Over the past year, new treatment innovations and improved access to advanced biologics have redefined therapeutic standards for both hematologic and solid tumors. Precision oncology technologies are enhancing early diagnosis and individualizing treatments to improve patient survival. Market expansion is supported by favorable government programs, higher healthcare investments, and evolving regulatory pathways. The oncology biopharmaceuticals sector continues to lead the shift toward precision medicine by customizing therapies according to each patient's molecular profile. The industry's growth is further supported by advancements in biologics, immunotherapies, and the increasing adoption of precision-based medical practices to address the urgent need for more effective cancer management worldwide.

The monoclonal antibodies segment held a 37.6% share in 2024 and is anticipated to reach USD 96 Billion by 2034, growing at a CAGR of 7%. Monoclonal antibodies remain a cornerstone of contemporary oncology, as they are highly specific biologic agents that bind to unique antigens expressed on cancer cells. These targeted therapies work by directly attacking tumor cells, interrupting tumor growth signaling, and stimulating immune activity to eliminate cancerous tissues. Compared to conventional chemotherapy, monoclonal antibodies offer a more favorable safety profile, minimizing off-target effects and enhancing treatment precision.

The lung cancer application segment generated USD 37.5 Billion in 2024. Lung cancer remains the most fatal cancer type globally, with non-small cell lung cancer (NSCLC) accounting for nearly 85% of all cases. The market has experienced a major transformation due to the growing availability of precision-based and immuno-oncology treatments. Modern therapeutic advancements focused on specific genetic and molecular targets have significantly improved patient outcomes and treatment success rates.

U.S. Oncology Biopharmaceuticals Market reached USD 51.9 Billion in 2024. Technological progress in artificial intelligence is revolutionizing cancer diagnostics and accelerating the development of next-generation oncology drugs. However, unequal access to these advanced treatments remains a persistent challenge, particularly among underrepresented groups. The U.S. continues to make strides in advancing biosimilars and personalized therapies, with strong investments aimed at improving affordability and enhancing patient access to cell-based and immune therapies.

Key participants in the Oncology Biopharmaceuticals Market include AbbVie, Amgen, AstraZeneca, Bayer, Biogen, Bristol-Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Sanofi, Takeda Pharmaceutical, Sandoz, Biocon, Celltrion, Adaptimmune, Legend Biotech, and Arcellx. To reinforce their position in the Global Oncology Biopharmaceuticals Market, major companies are focusing on strategic collaborations, mergers, and acquisitions to broaden their oncology pipelines and accelerate drug development. Firms are expanding their research partnerships with biotech innovators to co-develop targeted biologics and immunotherapies. Investment in advanced technologies such as AI, genomics, and molecular profiling is being prioritized to strengthen precision medicine capabilities. Companies are also working toward regulatory alignment to speed up product approvals and expand geographic reach.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Product type trends
  • 2.2.3 Cancer type trends
  • 2.2.4 Route of administration trends
  • 2.2.5 Drug type trends
  • 2.2.6 Distribution channel
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factors affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising global cancer incidence and aging population
    • 3.2.1.2 Advancements in immunotherapy and targeted biologics
    • 3.2.1.3 Expansion of biomarker-driven and precision oncology
    • 3.2.1.4 Increasing regulatory support for accelerated approvals
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of biologics and limited affordability in low-income regions
    • 3.2.2.2 Complex manufacturing and supply chain logistics
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expansion of tumor-agnostic and pan-cancer therapies
    • 3.2.3.2 Increased adoption of digital health and remote monitoring tools
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
    • 3.4.1.1 U.S.
    • 3.4.1.2 Canada
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Technology landscape
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Future market trends
• 3.7 Pipeline analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 Global
  • 4.2.2 North America
  • 4.2.3 Europe
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2034 ($ Bn)

• 5.1 Key trends
• 5.2 Monoclonal antibodies
• 5.3 Immune checkpoint inhibitors
• 5.4 Cell and gene therapies
• 5.5 Antibody-drug conjugates (ADCs)
• 5.6 Cancer vaccines
• 5.7 Other product types

Chapter 6 Market Estimates and Forecast, By Cancer Type, 2021 - 2034 ($ Bn)

• 6.1 Key trends
• 6.2 Lung cancer
• 6.3 Breast cancer
• 6.4 Colorectal cancer
• 6.5 Prostate cancer
• 6.6 Leukemia and lymphoma
• 6.7 Melanoma
• 6.8 Ovarian and cervical cancer
• 6.9 Other cancer types

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Bn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Parenteral
• 7.4 Other route of administration

Chapter 8 Market Estimates and Forecast, By Drug Type, 2021 - 2034 ($ Bn)

• 8.1 Key trends
• 8.2 Proprietary (Branded)
• 8.3 Biosimilars

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Bn)

• 9.1 Key trends
• 9.2 Hospital pharmacies
• 9.3 Drug stores and retail pharmacies
• 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Bn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 India
  • 10.4.3 Japan
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 AbbVie
• 11.2 Amgen
• 11.3 AstraZeneca
• 11.4 Bayer
• 11.5 Biogen
• 11.6 Bristol-Myers Squibb
• 11.7 Eli Lilly
• 11.8 F. Hoffmann-La Roche
• 11.9 GlaxoSmithKline
• 11.10 Johnson & Johnson
• 11.11 Merck
• 11.12 Novartis
• 11.13 Pfizer
• 11.14 Sanofi
• 11.15 Takeda Pharmaceutical
• 11.16 Sandoz
• 11.17 Biocon
• 11.18 Celltrion
• 11.19 Adaptimmune
• 11.20 Legend Biotech
• 11.21 Arcellx